Open AccessRole of plasma angiotensin II and angiotensin-converting enzyme 2 levels on prognosis and mortality in hypertensive patients with COVID-19
Author(s) -
Serap Biberoğlu,
Afşın İpekci,
İ̇brahim Ikizceli,
Fatih Çakmak,
Yonca Senem Akdeniz,
Altuğ Kanbakan,
Díldar Konukoğlu,
İbrahim Murat Bolayırlı,
Şermin Börekçi,
Seval Ürkmez,
Seda Özkan
Publication year - 2021
Publication title -
biomarkers in medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.652
H-Index - 44
eISSN - 1752-0371
pISSN - 1752-0363
DOI - 10.2217/bmm-2021-0121
Subject(s) - medicine , renin–angiotensin system , intensive care unit , angiotensin ii , angiotensin converting enzyme , mortality rate , angiotensin converting enzyme 2 , covid-19 , disease , blood pressure , infectious disease (medical specialty)
SARS-CoV-2 requires angiotensin-converting enzyme 2 (ACE2) to enter the cell. In our study, we aimed to investigate the role of angiotensin-converting enzyme 2 and angiotensin II plasma levels on prognosis and mortality in patients with isolated hypertension, patients with chronic diseases in addition to hypertension and patients with COVID-19 without comorbidities, in accordance with the use of renin-angiotensin-aldosterone system inhibitor. Materials & methods: In the study, patients diagnosed with COVID-19 were divided into three groups. Angiotensin II and ACE2 levels were compared by comorbidities, antihypertensive drugs used, intensive care hospitalization and termination of patients. The relationship between angiotensin II and ACE2 levels and service and intensive care times was investigated. Findings: A total of 218 patients were enrolled in our study, including 68 patients diagnosed with COVID-19 without comorbidities, 33 patients diagnosed with isolated hypertension and 117 patients with other chronic diseases in addition to hypertension. There was no statistically significant difference between the comorbid disease groups between angiotensin II and ACE2 levels of the patients enrolled in the study. The rate of patients admitted to the intensive care unit was 17.9%, and the mortality rate was 11.5%. Results: In our study, we did not obtain significant findings regarding angiotensin II and ACE2 levels on presentation that can be used in prognosis and mortality of COVID-19 patients and development of future treatment methods.